CHAPTER 10 228 10 46. Schoenen J, Manise M, Nonis R, Gérard P, Timmermans G. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention. Rev Neurol (Paris). 2020;176(10):788-803. 47. Greco R,Demartini C,Zanaboni AM,et al.The endocannabinoid system and related lipids as potential targets for the treatment of migrainerelated pain. Headache. 2022;62(3):227-240. 48. Fusco BM, Barzoi G, Agrò F. Repeated intranasal capsaicin applications to treat chronic migraine. Br J Anaesth. 2003;90(6):812. 49. Lambert GA, Davis JB, Appleby JM, et al. The effects of the TRPV1 receptor antagonist SB705498 on trigeminovascular sensitisation and neurotransmission. Naunyn Schmiedebergs Arch Pharmacol. 2009;380(4):311-325. 50. Aghazadeh Tabrizi M, Baraldi PG, Baraldi S, et al. Medicinal Chemistry, Pharmacology, and Clinical Implications of TRPV1 Receptor Antagonists. Med Res Rev. 2017;37(4):936-983. 51. Eltorp CT, Jansen-Olesen I, Hansen AJ. Release of calcitonin gene-related peptide (CGRP) from guinea pig dura mater in vitro is inhibited by sumatriptan but unaffected by nitric oxide. Cephalalgia. 2000;20(9):838-844. 52. Dodick DW, Ashina M, Brandes JL, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. SAGE Publications Ltd STM; 2018. p. 1026-1037. 53. Antonova M, Wienecke T, Maubach K, et al. The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache. J Headache Pain. 2011;12(5):551-559. 54. Cuttler C, Spradlin A, Cleveland MJ, Craft RM. Short- and Long-Term Effects of Cannabis on Headache and Migraine. J Pain. 2020;21(5-6):722-730. 55. Malek N, Starowicz K. Dual-Acting Compounds Targeting Endocannabinoid and Endovanilloid Systems-A Novel Treatment Option for Chronic Pain Management. Front Pharmacol. 2016;7:257. 56. Dallmann R, Viola AU, Tarokh L, Cajochen C, Brown SA. The human circadian metabolome. Proc Natl Acad Sci U S A. 2012;109(7):2625-2629. 57. Kasukawa T, Sugimoto M, Hida A, et al. Human blood metabolite timetable indicates internal body time. Proc Natl Acad Sci U S A. 2012;109(37):15036-15041. 58. Lehmann R. From bedside to bench-practical considerations to avoid pre-analytical pitfalls and assess sample quality for high-resolution metabolomics and lipidomics analyses of body fluids. Anal Bioanal Chem. 2021;413(22):55675585. 59. Chua EC, Shui G, Lee IT, et al. Extensive diversity in circadian regulation of plasma lipids and evidence for different circadian metabolic phenotypes in humans. Proc Natl Acad Sci U S A. 2013;110(35):14468-14473. 60. Trabado S, Al-Salameh A, Croixmarie V, et al. The human plasma-metabolome: Reference values in 800 French healthy volunteers; impact of cholesterol, gender and age. PLoS One. 2017;12(3):e0173615. 61. Darst BF, Koscik RL, Hogan KJ, Johnson SC, Engelman CD. Longitudinal plasma metabolomics of aging and sex. Aging (Albany N Y). 2019;11(4):1262-1282. 62. Sarchielli P, Pini LA, Coppola F, et al. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology. 2007;32(6):1384-1390. 63. Nattero G, Allais G, De Lorenzo C, et al. Relevance of prostaglandins in true menstrual migraine. Headache. 1989;29(4):233-238. 64. Tuca JO, Planas JM, Parellada PP. Increase in PGE2 and TXA2 in the saliva of common migraine patients. Action of calcium channel blockers. Headache. 1989;29(8):498-501. 65. Vardi J, Flechter S, Alguati A, Regev I, Ayalon D. Prostaglandin--E2 levels in the saliva of common migrainous women. Headache. 1983;23(2):59-61. 66. Sarchielli P, Alberti A, Codini M, Floridi A, Gallai V. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia. 2000;20(10):907-918. 67. Boheler KR, Volkova M, Morrell C, et al. Sex- and age-dependent human transcriptome variability: implications for chronic heart failure. Proc Natl Acad Sci U S A. 2003;100(5):2754-2759.
RkJQdWJsaXNoZXIy MTk4NDMw